

PATIENT EVIDENCE SUBMISSION TIP SHEET FOR A pCODR DRUG REVIEW

CADTH

pCODR



FOR EACH ASPECT OF THE SUBMISSION:

- Describe the number of patients from whom input was obtained
- Include patient demographics (age, sex, ethnicity, geographical location, number of prior lines of therapy)
- Exclude information on statistics and scientific published references
- Describe experiences of patients/caregivers that REFLECTS THE POPULATION WHO WILL USE THE PROPOSED DRUG (for example, if a drug is being tested in the curative setting, experiences of patients with metastatic disease may not be relevant)

GATHERING INFORMATION

1

- Who is the author of the submission?
- Are methods of data collection described?
- How many patients are there from each method of data collection?
- Please include data/insights beyond what is already published in the literature.

If possible, include input from patients who received the drug in question and patients who received no treatments/other therapies **in a similar clinical context**. Input from caregivers is also valuable.

EXPERIENCES WITH THIS TYPE OF CANCER

2

- What are the experiences of patients/caregivers with this cancer?
- According to patients/caregivers, what symptoms of the cancer are important to control?
- How are daily functions and quality of life affected?
- How does the cancer impact patients and caregivers with respect to finances and relationships?

Use of direct quotes can be very helpful.

Including specific and detailed experiences can be very helpful in providing context.

IMPACT OF CANCER TREATMENT ON CAREGIVERS

3

- How are daily routine and quality of life affected for the caregiver?
- What are some challenges that caregivers face?
- What concerns are unaddressed by current treatment?

Information should be obtained directly from caregivers.

PATIENT EVIDENCE SUBMISSION TIP SHEET FOR A pCODR DRUG REVIEW

CADTH

pCODR

CCAN
Canadian Cancer Action Network



RCLC
Réseau canadien de lutte contre le cancer



ARCC
Canadian Centre for Applied Research in Cancer Control



EXPERIENCES WITH *CURRENT* STANDARD TREATMENT

4

- How do patients/caregivers describe some of their experiences with current therapy?
- How effective is it in reducing side effects?
- How are daily functions and quality of life affected?
- What are some accessibility and financial implications?
- What concerns are unaddressed by current treatment?

Include information about current therapies that patients are taking.

Including specific experiences can be very helpful in providing context.

EXPECTATIONS FOR *NEW* TREATMENT

5

- What side effects of the treatment are important to control?
- What specific aspects of the treatment are important to manage?
- What side effects and magnitude of side effects are tolerable in exchange for better clinical outcomes?
- What financial and accessibility benefits are expected?

Information should be obtained from patients with no experience with the drug.

Include information on quality of life, daily functioning, side effects, etc.

EXPERIENCES WITH *NEW* TREATMENT

6

- How many patients have direct experience with the drug being reviewed?
- What do patients value about the drug under review? (e.g. longer survival, less side-effects, better QoL)
- What are some key side effects?
- What are some accessibility and financial implications?
- What concerns are unaddressed by new treatment?

Include information about how patients with experience are accessing the drug under review.

Include side effects that are most debilitating to quality of life, AND side effects that are tolerable.

Production of this Evidence Submission Tips Sheet has been made possible through a financial contribution from Health Canada, through the Canadian Partnership Against Cancer.

The views expressed herein represent the views of the Canadian Cancer Action Network.